Document:

Exhibit 10.1

 

Amendment
No. 1 to SHARE PURCHASE AGREEMENT

 

This Amendment No.
1 to Share Purchase Agreement (this “Amendment”) is effective as of April 27, 2018 by and among TNK Therapeutics,
Inc., a Delaware corporation (the “Purchaser”), Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”),
and Dayspring Ventures Limited, a private limited company registered in Jersey under company number 75238 with address at 4 Bond
Street, St Helier, Jersey JE2 3NP, as representative (the “Shareholders’ Representative”) of the
shareholders (the “Shareholders”) of Virttu Biologics Limited (the “Company”).

 

Recitals

 

Whereas,
the Purchaser, Sorrento, the Shareholders and the Shareholders’ Representative are parties to that certain Share Purchase
Agreement, dated as of April 27, 2017, pursuant to which, among other things, the Shareholders sold to the Purchaser and the Purchaser
purchased from the Shareholders all of the issued ordinary shares of 0.1p each in the capital of the Company (the “Share
Purchase Agreement”);

 

Whereas,
pursuant to Section 10.3 of the Share Purchase Agreement, the Share Purchase Agreement may not be amended, modified, altered or
supplemented except by written agreement between the Purchaser and the Shareholders’ Representative, provided that the provisions
of Sections 1.2(a), 1.4(b), 1.6, 1.7, 6.6, 6.8, 7.4 and 8.5(a) and Articles V and X thereof may not be amended without the consent
of Sorrento;

 

Whereas,
the Purchaser, Sorrento and the Shareholders’ Representative acknowledge and agree that a Qualified Financing has not occurred
and will not occur; and

 

Whereas,
the Purchaser, Sorrento and the Shareholders’ Representative wish to amend the Share Purchase Agreement, including portions
of Sections 1.4(b) and 8.5(a) thereof, to make certain modifications to the consideration payable to the Shareholders on the Financing
Due Date in the event a Qualified Financing does not occur on the terms set forth herein.

 

Now
Therefore, in consideration of the mutual covenants and agreements contained herein, and with reference to the above
recitals, the parties hereby agree as follows:

 

ARTICLE
1

AMENDMENTS

 

1.1 Amendment and
Restatement of Section 1.4(b). Section 1.4(b) of the Share Purchase Agreement
is hereby amended and restated in its entirety to read as follows:

 

“(b) In the
event a Qualified Financing does not occur, then (i) subject to Section 1.7 and Section 8.5(a), on the Financing
Due Date, Sorrento shall issue the Contingency Shares, free and clear of all Liens, and promptly thereafter deliver to the Shareholders’
Representative (for distribution to the Shareholders) the book entry statements representing the Contingency Shares in the name
of each Shareholder, in each case, for such number of shares of Sorrento Common Stock as is equal to the product of the total number
of Contingency Shares multiplied by the quotient obtained by dividing (A) the total number of Shares owned by such Shareholder
as of immediately prior to the Closing by (B) the total number of Shares outstanding as of immediately prior to the Closing, and
(ii) subject to Section 8.5(a), on or before June 27, 2018, Sorrento shall pay the Contingency Cash by wire transfer of
immediately available funds to the account designated by the Shareholders’ Representative in writing (for distribution to
the Shareholders), in each case, for such amount as is equal to the product of the total amount of Contingency Cash multiplied
by the quotient obtained by dividing (A) the total number of Shares owned by such Shareholder as of immediately prior to the Closing
by (B) the total number of Shares outstanding as of immediately prior to the Closing.”

 

     

     

    

 

1.2 Amendment and
Restatement of Section 6.8(c). Section 6.8(c) of the Share Purchase Agreement
is hereby amended and restated in its entirety to read as follows:

 

“(c) The Shareholders
have agreed that: (i) in the event a Qualified Financing occurs, (A) upon issuance of the Non-Escrow Shares, 6% of the Non-Escrow
Shares deliverable to the Shareholders’ Representative for distribution to the Shareholders (net of certain deductions as
specified in the Staff Incentive Scheme Rules) shall be held by the Shareholders’ Representative for the purposes of the
Staff Incentive Scheme (the “Non-Escrow Incentive Shares”), (B) upon release of the Escrow Shares from
escrow pursuant to the Escrow Agreement, 6% of the Escrow Shares deliverable to the Shareholders’ Representative for distribution
to the Shareholders (net of certain deductions as specified in the Staff Incentive Scheme Rules) shall be held by the Shareholders’
Representative for the purposes of the Staff Incentive Scheme (the “Escrow Incentive Shares”); and (ii)
in the event a Qualified Financing does not occur, (A) upon issuance of the Contingency Shares, 6% of the Contingency Shares deliverable
to the Shareholders’ Representative for distribution to the Shareholders (net of certain deductions as specified in the Staff
Incentive Scheme Rules) shall be held by the Shareholders’ Representative for the purposes of the Staff Incentive Scheme
(the “Contingency Incentive Shares” and, together with the Closing Incentive Shares, the Non-Escrow Incentive
Shares and the Escrow Incentive Shares, the “Incentive Shares”), and (B) upon the payment of the Contingency
Cash, 6% of the Contingency Cash deliverable to the Shareholders’ Representative for distribution to the Shareholders (net
of certain deductions as specified in the Staff Incentive Scheme Rules) shall be held by the Shareholders’ Representative
for the purposes of the Staff Incentive Scheme (the “Contingency Incentive Cash”). For the avoidance
of doubt, unless the Closing Incentive Shares, Non-Escrow Incentive Shares, Escrow Incentive Shares or Contingency Incentive Shares
have been sold by the Shareholders’ Representative in accordance with Section 6.8(d), such shares remain subject to
the offset mechanism in Section 8.5(a) to satisfy any Loss for which the Shareholders may be liable under Article VIII.”

 

1.3 Amendment and
Restatement of Section 6.8(d). Section 6.8(d) of the Share Purchase Agreement
is hereby amended and restated in its entirety to read as follows:

 

    2 

     

    

 

“(d) Once any
Incentive Shares are free from any restrictions on marketability, the Shareholders’ Representative will sell those Incentive
Shares and the proceeds of sale of each category of Incentive Shares shall be a bonus pool available under the Staff Incentive
Scheme (together the “Bonus Pools” and each a “Bonus Pool”); provided,
however, that the Contingency Incentive Cash shall be included in the Bonus Pool resulting from the sale of the Contingency
Incentive Shares.”

 

1.4 Amendment to
Section 8.1(a)(viii). The phrase “, the Contingency Cash” is hereby
inserted after the words “the Contingency Shares” in Section 8.1(a)(viii) of the Share Purchase Agreement.

 

1.5 Amendment and
Restatement Section 8.5(a)(x). Section 8.5(a)(x) of the Share Purchase
Agreement is hereby amended and restated in its entirety to read as follows:

 

“(x) by offsetting
such Losses against the amount of the Non-Escrow Shares, Contingency Shares or Contingency Cash to be delivered to the Shareholders’
Representative for the benefit of such Indemnifying Party, provided, however, that if an Indemnified Party in good faith has given
written notice of a Third-Party Claim containing a claim which has not been resolved in full prior to the date on which the Purchaser
would otherwise be required to procure the issue of the Contingency Shares or payment of the Contingency Cash, Sorrento shall not
be required to issue an amount of Contingency Shares or pay an amount of Contingency Cash equal to the amount described in each
such written notice of a Third-Party Claim, up to the total number of Contingency Shares and the total amount of the Contingency
Cash, until such resolution has taken place, whereupon Sorrento shall issue an amount of Contingency Shares or pay an amount of
Contingency Cash equal to the amount of the claim not resolved in the Indemnified Party’s favor,”

 

1.6 Amendment to
Exhibit A. Exhibit A to the Share Purchase Agreement is hereby amended by adding
a new defined term “Contingency Cash” between the defined terms “Confidential Information” and “Contingency
Shares”, which shall read as follows:

 

““Contingency
Cash” means such amount of cash in United States Dollars as is equal to 40% of the Estimated Purchase Price.”

 

1.7 Amendment to
Definition of “Aggregate Consideration”. The phrase “, the
Contingency Cash” is hereby inserted after the words “the Contingency Shares” in the definition of “Aggregate
Consideration” set forth in Exhibit A to the Share Purchase Agreement.

 

1.8 Amendment to
Definition of “Contingency Shares”. The reference to “80%”
in the definition of “Contingency Shares” set forth in Exhibit A to the Share Purchase Agreement is hereby deleted
and replaced with “40%”.

 

1.9 Amendment to
Definition of “Realized Purchase Price”. Section (c)(ii) of the
definition of “Realized Purchase Price” set forth in Exhibit A to the Share Purchase Agreement is hereby deleted and
replaced to read in its entirety as follows:

 

“if after the
Financing Due Date but a Qualified Financing has not occurred, in respect of any Losses which are offset against the Contingency
Shares, the product obtained by multiplying (x) the number of Contingency Shares issued pursuant to Section 1.4(b) by (y)
the closing price per share of the Sorrento Common Stock, as reported on the Nasdaq Capital Market as of the time at which such
shares of Sorrento Common Stock have been issued and are freely tradeable plus an amount equal to the Contingency Cash; plus”

 

    3 

     

    

 

ARTICLE
2

GENERAL PROVISIONS

 

2.1 Definitions.
Capitalized terms in this Amendment but not otherwise defined in this Amendment shall have the meanings set forth in the Share
Purchase Agreement.

 

2.2 Recitals.
The Recitals shall be deemed to form part of this Agreement and are binding on the parties hereto.

 

2.3 Continuing Effectiveness.
Except as modified by this Amendment, the Share Purchase Agreement shall remain in full force and effect and no party by virtue
of entering into this Amendment is waiving any rights it has under the Share Purchase Agreement, and once this Amendment is executed
by the parties hereto, all references in the Share Purchase Agreement to “the Agreement” or “this Agreement,”
as applicable, shall refer to the Share Purchase Agreement as modified by this Amendment.

 

2.4 Successors and
Assigns. No party to this Amendment may assign any of its rights or delegate any of its obligations under this Amendment without
the prior written consent of the other parties to this Amendment. Subject to the preceding sentence, this Amendment shall apply
to, be binding in all respects upon and inure to the benefit of the successors and permitted assigns of the parties to this Amendment.

 

2.5 Governing Law;
Venue. This Amendment, the relationship of the parties hereto and any claims or disputes arising under or relating to this
Amendment shall be governed by and construed in accordance with Section 10.6 of the Share Purchase Agreement.

 

2.6 Execution of Amendment; Counterparts;
Electronic Signatures.

 

(a) This Amendment
may be executed in several counterparts, each of which shall be deemed an original and all of which, when taken together, shall
constitute one and the same instrument, and shall become effective when counterparts have been signed by each of the parties to
this Amendment and delivered to the other parties to this Amendment; it being understood that all parties to this Amendment need
not sign the same counterparts.

 

(b) This Amendment
and any amendments to this Amendment may be executed in one or more counterparts, each of which shall be enforceable against the
parties to this Amendment that execute such counterparts, and all of which together shall constitute one and the same instrument.
Facsimile and “.pdf” copies of signed signature pages shall be deemed binding originals and no party to this Amendment
shall raise the use of facsimile machine or electronic transmission in “.pdf” as a defense to the formation of a contract.

 

    4 

     

    

 

In
Witness Whereof, the parties have duly caused this Amendment No. 1 to Share Purchase Agreement to be executed as of
the day and year first above written.

 

	THE PURCHASER	 	SHAREHOLDERS’ REPRESENTATIVE
	TNK Therapeutics, Inc.	 	Dayspring Ventures Limited
	 	 	 	 	 
	 	 	 	 	 
	By:	/s/ Henry Ji, Ph.D.	 	By:	/s/ Daniel Young
	Name: Henry Ji, Ph.D.	 	Name: Daniel Young
	Title: Chief Executive Officer	 	Title: Director
	 	 	 	 	 
	SORRENTO	 	 	 
	Sorrento Therapeutics, Inc.	 	 	 
	 	 	 	 
	 	 	 	 
	By:	/s/ Henry Ji, Ph.D.	 	 	 
	Name: Henry Ji, Ph.D.	 	 	 
	Title: Chairman of the Board, President and

                                                       Chief Executive Officer
	 	 	 

  

    [Signature Page to Amendment No. 1 to Share Purchase Agreement]Exhibit 4.1

 

INVESTORS’ RIGHTS AGREEMENT

 

THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 22, 2017 by and among Scholar Rock Holding Corporation, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”

 

RECITALS

 

WHEREAS, the Company and certain of the Investors are parties to the Series C Preferred Stock Purchase Agreement of even date herewith (as the same may be amended or restated from time to time, the “Purchase Agreement”); and

 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce such Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement.

 

NOW, THEREFORE, the parties hereby agree as follows:

 

1.                                    Definitions. For purposes of this Agreement:

 

1.1                                   “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital or other investment fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment advisor with, such Person.

 

1.2                                  “Artal” means Artal International S.C.A. and its Affiliates.

 

1.3                                   “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as the same may be amended or restated from time to time.

 

1.4                                  “Common Stock” means shares of the Company’s common stock, par value $0.001 per share.

 

1.5                                   “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the development and commercialization of novel biologic therapeutic agents to treat disease, but shall not include (i) any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding equity of any

 

 

Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor or (ii) any Fidelity Investor.

 

1.6                                  “Damages” means any loss, damage, claim or liability Goint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

1.7                                   “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants.

 

1.8                                  “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

1.9                                 “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.

 

1.10                            “Fidelity Investor” means each Investor advised or subadvised by Fidelity Management & Research Company or one of its Affiliates as of the date hereof.

 

1.11                           “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.

 

1.12                            “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 

1.13                          “GAAP” means generally accepted accounting principles in the United States.

 

2

 

1.14                           “Holder” means any holder of Registrable Securities who is a party to this Agreement.

 

1.15                           “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein.

 

1.16                            “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 

1.17                            “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 

1.18                           “Major Investor” means (i) any Investor that, individually or together with such Investor’s Affiliates, holds at least 1,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof), and (ii) any Fidelity Investor that holds any Registrable Securities.

 

1.19                           “New Securities” means, collectively, equity secunt1es of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities.

 

1.20                           “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.21                           “Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock.

 

1.22                           “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement thereof; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement.

 

1.23                   “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or

 

3

 

indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.

 

1.24                           “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof.

 

1.25                           “SEC” means the Securities and Exchange Commission.

 

1.26                           “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

 

1.27                           “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

1.28                           “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

1.29                           “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6.

 

1.30                           “Preferred Director” means any director of the Company that the holders of record of the Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation.

 

1.31                           “Series A Preferred Stock” means shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series A-4 Preferred Stock.

 

1.32                           “Series A-1 Preferred Stock” means shares of the Company’s Series A-1 Preferred Stock, par value $0.001 per share.

 

1.33                           “Series A-2 Preferred Stock” means shares of the Company’s Series A-2 Preferred Stock, par value $0.001 per share.

 

1.34                           “Series A-3 Preferred Stock” means shares of the Company’s Series A-3 Preferred Stock, par value $0.001 per share.

 

1.35                           “Series A-4 Preferred Stock” means shares of the Company’s Series A-4 Preferred Stock, par value $0.001 per share.

 

1.36                           “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.001 per share.

 

1.37                           “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.001 per share.

 

4

 

2.                                     Registration Rights. The Company covenants and agrees as follows:

 

2.1                    Demand Registration.

 

(a)                  Form S-1 Demand.  If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least eighty percent (80%) of the Registrable Securities then outstanding (the “Requisite Holders”) that the Company file a Form S-1 registration statement with respect to at least twenty (20%) of the Registrable Securities then outstanding, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.l(c) and 2.3.

 

(b)                  Form S-3 Demand.  If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $10.0 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.l(c) and 2.3.

 

(c)                   Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors (the “Board of Directors”) it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the Company

 

5

 

may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period other than an Excluded Registration.

 

(d)                        The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.l(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.l(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.l(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.l(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2. l(d).

 

2.2                      Company Registration. Following the IPO, if the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6.

 

2.3                           Underwriting Requirements.

 

(a)                        If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the

 

6

 

Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities· through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.

 

(b)                  In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters

 

7

 

make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(a) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.

 

2.4                   Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

 

(a)                  prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to ninety (90) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;

 

(b)                  prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

 

(c)                   furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;

 

(d)                  use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;

 

8

 

(e)                   in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;

 

(f)                    use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;

 

(g)                   provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(h)                  promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

 

(i)                      notify each selling Holder, promptly after the Com,pany receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 

(j)                     after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.

 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 

2.5                Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.

 

2.6                Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to

 

9

 

exceed $35,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall- not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.l(a) or 2.l(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.l(b ). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.

 

2.7                Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

 

2.8                            Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:

 

(a)                              To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel, accountants and investment advisers for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.

 

(b)                              To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the

 

10

 

Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.

 

(c)       Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8.

 

(d)       To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate losses,

 

11

 

claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.

 

(e)       Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control.

 

(f)        Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 

2.9      Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:

 

(a)       make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;

 

(b)       use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 

12

 

(c)       furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) solely to the extent not available on EDGAR, a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).

 

2.10    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Requisite Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9.

 

2.11    “Market Stand-off’ Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (held immediately before the effective date of the registration statement for the IPO), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 (A) shall apply only to the IPO, (B) shall not apply to shares of Common Stock acquired in the IPO or in the open market following the IPO and (C) shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors and all stockholders individually

 

13

 

owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. If any of the obligations described in this Subsection 2.11 are waived or terminated with respect to any of the securities of any such Holder, officer, director or greater than one-percent stockholder (in any such case, the “Released Securities”), the foregoing provisions shall be waived or terminated, as applicable, to the same extent and with respect to the same percentage of securities of each Holder as the percentage of Released Securities represent with respect to the securities held by the applicable Holder, officer, director or greater than one-percent stockholder. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144 to be bound by the terms of this Agreement.

 

2.12      Restrictions on Transfer.

 

(a)       The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.

 

(b)       Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

14

 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12.

 

(c)       The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or, following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that, with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.

 

2.13      Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of:

 

(a)       the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation;

 

(b)       following the IPO, such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of,all of such Holder’s shares without limitation during a three-month period without registration (and without the requirement for the Company to be in compliance with the current public information required under Rule 144(c)(l)); and

 

15

 

(c)       the third (3rd) anniversary of the IPO.

 

3.        Information and Observer Rights.

 

3.1      Delivery of Financial Statements. The Company shall deliver to  each Major Investor:

 

(a)          as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company (i) an unaudited balance sheet as of the end of such year, (ii) unaudited statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the budget and business plan for such year prepared in the prior fiscal year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) an unaudited statement of stockholders’ equity as of the end of such year, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);

 

(b)       as soon as practicable, but in any event within one hundred eighty (180) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the budget and business plan for such year prepared in the prior fiscal year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements prepared in accordance with GAAP audited and certified by independent public accountants of regionally recognized standing selected by the Company;

 

(c)       as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);

 

(d)       as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP);

 

(e)       such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this

 

16

 

Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.

 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.

 

The Company shall promptly and accurately respond, and shall use its best efforts to cause its transfer agent to promptly respond, to requests for information made on behalf of any Fidelity Investor or Artal relating to (i) accounting or securities law matters required in connection with its audit or (ii) the actual holdings of such Fidelity Investor and Artal, including in relation to the total outstanding shares; provided, however, that the Company shall not be obligated to provide any such information that could reasonably result in a violation of applicable law or conflict with a confidentiality obligation of the Company.

 

3.2         Inspection. The Company shall permit each Major Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

3.3         Termination of Information Rights. The covenants set forth in Subsections 3.1, through 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first; provided, that, with respect to clause (iii), the covenants set forth in Section 3.1 shall only terminate if the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded

 

17

 

securities unless the Investors receive financial information from the acquiring company or other successor to the Company comparable to those set forth in Section 3.1.

 

3.4      Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding the foregoing, in the case of an Investor that is (i) a registered investment company within the meaning of the Investment Company Act of 1940, as amended, or (ii) is advised by a registered investment adviser or Affiliates thereof, such Investor may identify the Company and the value of such Investor’s security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies and respond to examinations, demands, requests or reporting requirements of a regulatory authority without prior notice to or consent from the Company.

 

4.                                     Rights to Future Stock Issuances.

 

4.1         Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself and (ii) its Affiliates.

 

(a)          The Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities.

 

(b)          By notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which

 

18

 

equals the proportion that the Common Stock then held by such Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.l(b) shall occur within the later of one hundred twenty (120) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).

 

(c)       If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.l(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.l(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Subsection 4.1.

 

(d)         The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); and (ii) shares of Common Stock issued in the IPO.

 

(e)           Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this Subsection 4.1, the Company may elect to give notice to the Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Investor, maintain such Investor’s percentage-ownership position, calculated as set forth in Subsection 4.l(b) before giving effect to the issuance of such New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is given to the Investors.

 

19

 

(f)        In the event that the rights of an Investor to purchase New Securities under this Subsection 4.1 are waived with respect to a particular offering of New Securities without such Investor’s prior written consent (a “Waived Investor”) and any Investor that participated in waiving such rights actually purchases New Securities in such offering, then the Company shall grant, and hereby grants, each Waived Investor the right to purchase, in a subsequent closing of such issuance on substantially the same terms and conditions, the same percentage of its full pro rata share of such New Securities as the highest percentage of any such purchasing Investor.

 

4.2         Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate oflncorporation, whichever event occurs first.

 

5.        Additional Covenants.

 

5.1      Insurance. The Company shall use its commercially reasonable efforts to maintain from financially sound and reputable insurers Directors and Officers liability insurance, in an amount and on terms and conditions satisfactory to the Board of Directors, until such time as the Board of Directors determines that such insurance should be discontinued.

 

5.2      Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) each key employee to enter into a one (1) year noncompetition and nonsolicitation agreement, in the form attached hereto as Exhibit A.

 

5.3      Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. The Company shall not materially amend, modify, terminate, waive or otherwise alter, in whole or in part, any of the agreements referred to in Section 5.2 or this 5.3 without the consent of all the Preferred Directors.

 

5.4      Matters Requiring Investor Director Approval. So long as the holders of Preferred Stock are entitled to elect at least one Preferred Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote of all of the Preferred Directors then in office:

 

20

 

(a)                  approve an operating budget for any fiscal year;

 

(b)                  hire any employee for the Company or its subsidiaries with a compensation package greater than $100,000 per annum, unless provided for in the budget;

 

(c)                   pledge or grant a security interest in any assets of the Company or any of its subsidiaries;

 

(d)                  make guarantees of third-party loans to employees or of obligations of subsidiaries, except in the ordinary course of business;

 

(e)                   issue any options to purchase Common Stock or other securities convertible or exercisable into Common Stock;

 

(f)                    enter into any agreements, including but not limited to leases, that obligate the Company or its subsidiaries to make aggregate annual payments in excess of $100,000, unless provided for in the budget;

 

(g)                   any establishment of, amendment to, or increase of the number of units available for issuance under, any employee incentive plan, similar equity compensation plan or other arrangement for the grant of equity compensation awards;

 

(h)                  change the principal business of the Company, enter new lines of business, or exit the current line of business;

 

(i)                      incur any indebtedness in excess of $250,000, individually or in the aggregate, or acquire any asset or assets with a value in excess of $100,000 in a single transaction or a series of related transactions, unless provided for in the budget approved by the Board of Directors;

 

(j)                     create any subsidiary of this Company or transfer any of the Company’s assets to any subsidiary of this Company; or

 

(k)                  sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business.

 

5.5                          Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. In the event the Board of Directors establishes any committees, the Board of Directors shall upon the request of a Preferred Director appoint such Preferred Director as a member of the applicable committee. In addition, in the event the Board of Directors establishes any subsidiaries, the Company shall upon request of a Preferred Director, appoint such Preferred Director as a director of such subsidiary.

 

21

 

5.6                          Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case maybe.

 

5.7                          Right to Conduct Activities.  The Company acknowledges that the execution of this Agreement shall in no way be construed to prohibit or restrict Artal, the Fidelity Investors, Fidelity or Fidelity’s other investment advisory clients from maintaining, making or considering investments in public or private companies, including, without limitation, companies that may compete either directly or indirectly with the Company (“Other Companies”), or from otherwise operating in the ordinary course of business. Furthermore, the Company understands and acknowledges that the Company’s confidential information may be used by Artal, the Fidelity Investors, Fidelity or their respective Affiliates for internal purposes in the ordinary course of business, including, without limitation, in connection with evaluating investment opportunities and making investments in Other Companies on behalf of funds and accounts managed by Artal, Fidelity, or their Affiliates, but specifically excluding disclosing or otherwise providing such confidential information to anyone other than Artal, the Fidelity Investors, Fidelity or their respective Affiliates.

 

5.8                          Termination of Covenants.  The covenants set forth in this Section 5, except for Subsection 5.6, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first.

 

6.                          Miscellaneous.

 

6.1                          Successors and Assigns.  The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) or, if less, all of the Registrable Securities held by such Holder; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family

 

22

 

Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.

 

6.2                          Governing Law.  This Agreement shall be governed by the internal law of the State of Delaware.

 

6.3                          Counterparts.  This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

6.4                          Titles and Subtitles.  The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.

 

6.5                          Notices.  All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy (which shall not constitute notice) shall also be sent to Goodwin Procter, 100 Northern Avenue, Boston, MA 02110, Attention: Kingsley L. Taft, Esq.

 

6.6                          Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite Holders; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that (i) Sections 2.11, 3.1 and 3.3 shall not

 

23

 

be modified, supplemented, amended or waived, in whole or in part, in a manner that adversely affects the Fidelity Investors, without the prior written consent of the Fidelity Investors holding a majority of the Registable Securities held by all Fidelity Investors and (ii) any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. In addition, Section 4.1(e) and this Subsection 6.6 may be amended and the observance thereof waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of Artal International S.C.A. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.

 

6.7                          Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.

 

6.8                          Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 

6.9                          Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares Preferred Stock after the date hereof, any purchaser of such shares may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.

 

6.10                   Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.

 

24

 

6.11                   Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

6.12                   Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company.

 

6.13                   Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of State of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of State of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

[Remainder of Page Intentionally Left Blank]

 

25

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
 
    	
SCHOLAR   ROCK HOLDING CORPORATION
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Nagesh   Mahanthappa
    
	
 
    	
Name:   
    	
Nagesh   Mahanthappa
    
	
 
    	
Title:   
    	
CEO   and President
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
 
    	
ARTAL INTERNATIONAL S.C.A.
    
	
 
    	
 
    
	
 
    	
By   Artal International Management S.A., its
    
	
 
    	
Managing   Partner
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/   Anne Goffard
    
	
 
    	
Name:
    	
Anne   Goffard
    
	
 
    	
Title:
    	
Managing   Director
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
 
    	
/s/   Timothy Springer
    
	
 
    	
Timothy Springer
    
	
 
    	
 
    
	
 
    	
TAS   PARTNERS, LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Timothy Springer
    
	
 
    	
Name:
    	
Timothy   Springer
    
	
 
    	
Title:
    	
Member
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
 
    	
REDMILE CAPITAL FUND, LP
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Jeremy Green
    
	
 
    	
Name: 
    	
Jeremy Green
    
	
 
    	
Title: 
    	
Managing Member of the   General Partner and the Investment Manager
    
	
 
    	
 
    
	
 
    	
REDMILE CAPITAL OFFSHORE FUND,   LTD.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Jeremy Green
    
	
 
    	
Name: 
    	
Jeremy Green
    
	
 
    	
Title: 
    	
Managing Member of the   Investment Manager
    
	
 
    	
 
    
	
 
    	
REDMILE CAPITAL OFFSHORE FUND   II, LTD.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Jeremy Green
    
	
 
    	
Name: 
    	
Jeremy Green
    
	
 
    	
Title: 
    	
Managing Member of the   Investment Manager
    
	
 
    	
 
    
	
 
    	
REDMILE BIOPHARMA INVESTMENTS   I, L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Jeremy Green
    
	
 
    	
Name: 
    	
Jeremy Green
    
	
 
    	
Title: 
    	
Managing Member of the   Management
    
	
 
    	
Company and the General   Partner
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
ECOR1 CAPITAL FUND, L.P.
    	
 
    
	
 
    	
 
    
	
By: 
    	
EcoR1   Capital, LLC
    	
 
    
	
Its:   
    	
General   Partner
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Oleg   Nodelman
    	
 
    
	
Name:   
    	
Oleg   Nodelman
    	
 
    
	
Title:   
    	
Founder
    	
 
    
	
 
    	
 
    
	
ECOR1 CAPITAL FUND QUALIFIED, L.P.
    	
 
    
	
 
    	
 
    
	
By: 
    	
EcoR1   Capital, LLC
    	
 
    
	
Its:   
    	
General   Partner
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Oleg   Nodelman
    	
 
    
	
Name:   
    	
Oleg   Nodelman
    	
 
    
	
Title:   
    	
Founder
    	
 
    

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
POLARIS VENTURE   PARTNERS VI, L.P.
    	
 
    
	
By: POLARIS VENTURE   MANAGEMENT CO. VI, L.L.C.
    	
 
    
	
ITS: GENERAL PARTNER
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Max Eisenberg
    	
 
    
	
 
    	
Max Eisenberg
    	
 
    
	
 
    	
Attorney-in-fact
    	
 
    
	
 
    	
 
    
	
POLARIS VENTURE   PARTNERS FOUNDERS’ FUND VI, L.P.
    	
 
    
	
By: POLARIS VENTURE   MANAGEMENT CO. VI, L.L.C.
    	
 
    
	
ITS: GENERAL PARTNER
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Max Eisenberg
    	
 
    
	
 
    	
Max Eisenberg
    	
 
    
	
 
    	
Attorney-in-fact
    	
 
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
 
    	
KPC VENTURE CAPITAL LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Robert K. Kraft
    
	
 
    	
Name:
    	
Robert K. Kraft
    
	
 
    	
Title:
    	
Sole Director of its   Manager
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
JAK LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Jonathan A. Kraft
    
	
 
    	
Name:
    	
Jonathan A. Kraft
    
	
 
    	
Title:
    	
Manager
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
ARCH Venture Fund VIII, L.P.
    	
 
    
	
 
    	
 
    
	
By:
    	
ARCH Venture Partners   VIII, L.P.
    	
 
    
	
Its:
    	
General Partner
    	
 
    
	
By:
    	
ARCH Venture Partners   VIII, LLC
    	
 
    
	
Its:
    	
General Partner
    	
 
    
	
 
    	
 
    
	
/s/ Mark   McDonnell
    	
 
    
	
Managing Director
    	
 
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above,

 

	
 
    	
FIDELITY ADVISOR SERIES VII:   FIDELITY 
    
	
 
    	
ADVISOR BIOTECHNOLOGY FUND
    
	
 
    	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Colm Hogan
    
	
 
    	
Name: 
    	
Colm Hogan
    
	
 
    	
Title: 
    	
Authorized Signatory
    
	
 
    	
 
    
	
 
    	
FIDELITY SELECT PORTFOLIOS:
    
	
 
    	
BIOTECHNOLOGY PORTFOLIO
    
	
 
    	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Colm Hogan
    
	
 
    	
Name:
    	
Colm Hogan
    
	
 
    	
Title:
    	
Authorized Signatory
    
	
 
    	
 
    
	
 
    	
FIDELITY MT. VERNON STREET   TRUST: 
    
	
 
    	
FIDELITY SERIES GROWTH COMPANY FUND
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Colm Hogan
    
	
 
    	
Name: 
    	
Colm Hogan
    
	
 
    	
Title:
    	
Authorized Signatory
    
	
 
    	
 
    
	
 
    	
FIDELITY GROWTH COMPANY
    
	
 
    	
COMMINGLED POOL
    
	
 
    	
BY: FIDELITY   MANAGEMENT & TRUST CO.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Colm Hogan
    
	
 
    	
Name:
    	
Colm Hogan
    
	
 
    	
Title:
    	
Authorized Signatory
    
	
 
    	
 
    
	
 
    	
FIDELITY MT. VERNON STREET   TRUST:
    
	
 
    	
FIDELITY GROWTH COMPANY FUND
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Colm Hogan
    
	
 
    	
Name:
    	
Colm Hogan
    
	
 
    	
Title:
    	
Authorized Signatory
    

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	
Cormorant   Private Healthcare Fund I, LP 
    	
 
    
	
 
    	
 
    
	
By:
    	
Cormorant   Private Healthcare GP, LLC
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Bihua   Chen
    	
 
    
	
Name:
    	
Bihua   Chen
    	
 
    
	
Title:
    	
Managing   Member of the GP
    	
 
    
	
 
    	
 
    	
 
    
	
Cormorant   Global Healthcare Master Fund, LP
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
Cormorant   Global Healthcare GP, LLC
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Bihua Chen
    	
 
    
	
Name:
    	
Bihua   Chen
    	
 
    
	
Title:
    	
Managing   Member of the GP
    	
 
    
	
 
    	
 
    	
 
    
	
CRMA   SPV, L.P.
    	
 
    
	
 
    	
 
    	
 
    
	
By: 
    	
Cormorant   Asset Management, LLC
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Bihua   Chen
    	
 
    
	
Name:
    	
Bihua   Chen, CEO/CIO
    	
 
    
	
Its:
    	
Attorney-in-Fact
    	
 
    

 

 

SCHEDULE A 

Investors

 

	
Artal International SCA
    
	
44, Rue de la Vallée
    
	
L-2661 Luxembourg
    
	
Attn : Anne Goffard
    
	
 
    
	
With copies to:
    
	
 
    
	
The Invus Group   LLC   
    
	
750 Lexington Avenue
    
	
New York, NY 10022
    
	
Attn: Philippe J.   Amouyal; and
    
	
 
    
	
Patterson Belknap   Webb & Tyler LLP
    
	
1133 Avenue of the   Americas
    
	
New York, NY 10036-6710
    
	
Attn: Peter J.   Schaeffer, Esq.
    
	
 
    
	
Redmile Capital Fund,   LP
    
	
One Letterman Drive
    
	
Building D   Suite D3-300
    
	
San Francisco, CA 94129
    
	
Telephone: 415-489-9980
    
	
Email:   operations@redmilegrp.com
    
	
Attn: Josh Garcia, CFO
    
	
 
    
	
Redmile Capital   Offshore Fund, Ltd.
    
	
One Letterman Drive
    
	
Building D   Suite D3-300
    
	
San Francisco, CA 94129
    
	
Telephone: 415-489-9980
    
	
Email:   operations@redmilegrp.com
    
	
Attn: Josh Garcia, CFO
    
	
 
    
	
Redmile Capital   Offshore Fund II, Ltd. 
    
	
One Letterman Drive
    

 

 

	
Building D   Suite D3-300
    
	
San Francisco, CA 94129
    
	
Telephone: 415-489-9980
    
	
Email:   operations@redmilegrp.com
    
	
Attn: Josh Garcia, CFO
    
	
 
    
	
Redmile Biopharma   Investments I, L.P.
    
	
One Letterman Drive
    
	
Building D   Suite D3-300
    
	
San Francisco, CA 94129
    
	
Telephone: 415-489-9980
    
	
Email:   operations@redmilegrp.com
    
	
Attn: Josh Garcia, CFO
    
	
 
    
	
Fidelity Mt. Vernon   Street Trust: Fidelity Series Growth Company Fund
    
	
State Street   Bank & Trust
    
	
PO Box 5756
    
	
Boston, Massachusetts   02206
    
	
Attn: WAVELENGTH + CO   Fidelity Mt.
    
	
Vernon Street Trust:   Fidelity Series Growth Company Fund
    
	
Email: SSBCORPACTIONS@StateStreet.com
    
	
Fax number:   617-988-9110
    
	
 
    
	
Fidelity Growth Company   Commingled Pool
    
	
c/o Brown Brothers   Harriman & Co.
    
	
Attn: Corporate Actions   /Vault
    
	
140 Broadway
    
	
New York, NY 10005
    
	
BBH.Fidelity.CA.Notifications@BBH.com
    
	
 
    
	
Fidelity Mt. Vernon   Street Trust: Fidelity Growth Company Fund
    
	
BNY Mellon
    
	
Attn: Stacey Wolfe
    
	
525 William Penn Place   Rm 0400   
    
	
Pittsburgh, PA 15259 
    
	
Email: FidelityCorporateEvents@bnymellon.com
    
	
Fax number:   412-236-1012
    
	
 
    
	
Fidelity Advisor   Series VII: Fidelity Advisor Biotechnology Fund
    
	
State Street   Bank & Trust
    
	
PO Box 5756
    
	
Boston, Massachusetts   02206
    
	
Attn: Bangle &   Co fbo Fidelity Advisor
    
	
Series VII:   Fidelity Advisor Biotechnology Fund
    
	
Email: SSBCORPACTIONS@StateStreet.com
    
	
Fax number:   617-988-9110
    

 

 

	
Fidelity Select   Portfolios: Biotechnology Portfolio
    
	
Brown Brothers   Harriman & Co.
    
	
525 Washington Blvd
    
	
Jersey City NJ 07310
    
	
Attn: Michael Lerman   15th Floor
    
	
Corporate Actions
    
	
Email:   michael.lerman@bbh.com
    
	
Fax number: 617   772-2418
    
	
 
    
	
Cormorant Global   Healthcare Master Fund, LP
    
	
200 Clarendon Street,   52nd Floor
    
	
Boston, MA 02116
    
	
 
    
	
Cormorant Private   Healthcare Fund I, LP  
    
	
200 Clarendon Street,   52nd Floor
    
	
Boston, MA 02116
    
	
 
    
	
CRMA SPV, L.P.
    
	
PO Box 309
    
	
Ugland House
    
	
Grand Cayman
    
	
KY1-1104 Cayman Islands
    
	
 
    
	
ARCH Venture Fund VIII,   L.P.
    
	
ARCH Venture Partners
    
	
Attn: Mark McDonnell
    
	
8755 West Higgins Road
    
	
Suite 1025
    
	
Phone 773 380 6600
    
	
Fax 773 380 6606
    
	
Email   mmcdonnell@archventure.com
    
	
 
    
	
Polaris Venture   Partners VI, L.P.
    
	
1000 Winter Street
    
	
Suite 3350
    
	
Waltham, MA 02451
    
	
 
    
	
Polaris Venture   Partners Founders’ Fund VI, L.P.
    
	
1000 Winter Street
    
	
Suite 3350
    
	
Waltham, MA 02451
    

 

 

	
Timothy Springer
    
	
TAS Partners, LLC
    
	
36 Woodman Road
    
	
Newton, MA 02467
    
	
 
    
	
EcoR1 Capital Fund, LP
    
	
409 Illinois Street
    
	
San Francisco, CA 94158
    
	
 
    
	
EcoR1 Capital Fund   Qualified, LP
    
	
409 Illinois Street
    
	
San Francisco, CA 94158
    
	
 
    
	
KPC Venture Capital,   LLC
    
	
 
    
	
JAKII LLC
    

 

 

EXHIBIT A

 

Form Of Noncompetition and Nonsolicitation Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]